The raised guidance and strong Q1 beat confirm accelerating momentum in Cortrophin Gel and the generics cash flow engine. With a $100M buyback authorization and net leverage at 1.3x, ANI has ample capacity for further capital deployment. Watch for the Phase 4 gout trial data and the full gout sales force deployment by end of Q2 2026 as key catalysts.
Price Chart
Executive Summary
ANI Pharmaceuticals published an updated May 2026 investor presentation via an 8-K (Item 7.01), reiterating and raising its full-year 2026 guidance originally provided on May 8, 2026. The presentation highlights strong Q1 2026 results with total net revenue of $237.5M (+20% YoY) and adjusted non-GAAP EBITDA of $63.0M (+24% YoY), driven by Cortrophin Gel momentum and a new IP license fee. The company raised its 2026 revenue guidance to $1.08B-$1.14B (from $1.055B-$1.115B) and adjusted EBITDA guidance to $285M-$300M (from $275M-$290M), and authorized a new $100M share repurchase program.
Key Facts
- Q1 2026 total net revenue of $237.5M, up 20% YoY from $197.1M
- Q1 2026 adjusted non-GAAP EBITDA of $63.0M, up 24% YoY from $50.7M
- Raised full-year 2026 total net revenue guidance to $1.08B-$1.14B (prior: $1.055B-$1.115B)
- Raised full-year 2026 adjusted non-GAAP EBITDA guidance to $285M-$300M (prior: $275M-$290M)
- Cortrophin Gel net revenue guided to $540M-$575M in 2026, representing ~60% YoY growth
- Board authorized a new $100M share repurchase program
- Out-licensed IP to Harmony Biosciences for $15M upfront fee recognized in Q1 2026, plus up to $10M in milestones
- Cash of $311M as of March 31, 2026; net leverage of ~1.3x
Financial Impact
Raised 2026 revenue guidance by $25M at midpoint ($1.11B vs prior $1.085B) and EBITDA guidance by $10M at midpoint ($292.5M vs prior $282.5M). Q1 revenue grew 20% YoY and EBITDA grew 24% YoY.
Risk Factors
- Cortrophin Gel growth dependent on continued market expansion and gout launch execution
- Blended royalty rate to Merck on Cortrophin Gel expected in high-20% range, pressuring gross margin
- Generics business faces pricing pressure and FDA competition risks
- ILUVIEN return to growth not yet confirmed by hard data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001023024-26-000054 |
| Document: ani-20260513.htm | 0001023024-26-000054 |
| Document: 0001023024-26-000054-index-headers.html | 0001023024-26-000054 |
| Document: 0001023024-26-000054-index.html | 0001023024-26-000054 |
| Document: 0001023024-26-000054.txt | 0001023024-26-000054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $72.11 $77.91 | ▲ +8.04% | ▲ +7.23% | $71.97 (−0.19%) |
Sep 1, 2026 4w ago | Insider Cluster | $73.06 $71.46 | ▼ −2.19% | ▼ −1.23% | $71.97 (−1.49%) |
Aug 24, 2026 5w ago | 8-K | $74.17 $73.25 | ▼ −1.24% | ▼ −1.71% | $71.97 (−2.97%) |
Aug 13, 2026 7w ago | Insider Cluster | $74.77 $77.32 | ▲ +3.41% | ▲ +5.37% | $71.97 (−3.74%) |
Aug 7, 2026 8w ago | 8-K | $78.25 $76.54 | ▼ −2.19% | ▼ −2.58% | $71.97 (−8.03%) |
Jul 16, 2026 11w ago | Court Ruling | $81.92 $78.53 | ▼ −4.14% | ▼ −2.47% | $71.97 (−12.15%) |
Jul 13, 2026 11w ago | Press Release | $81.08 $79.20 | ▼ −2.32% | ▼ −1.53% | $71.97 (−11.24%) |
Jun 15, 2026 15w ago | Insider Cluster | $83.00 $82.94 | ▼ −0.07% | ▲ +2.16% | $71.97 (−13.29%) |
Jun 11, 2026 16w ago | Insider Cluster | $81.65 $80.52 | ▼ −1.38% | ▼ −1.82% | $71.97 (−11.86%) |
May 21, 2026 19w ago | 8-K | $82.72 $76.71 | ▼ −7.27% | ▼ −8.92% | $71.97 (−13.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access